采用MonolixSuite软件发表的部分参考文献汇总（2026年1-7月）

凡默谷技术部挑选了2026年1-7月全球采用MonolixSuite软件发表或涉及MonolixSuite的部分应用文章。希望对您的业务或专业学习有所帮助。

 中国用户发表的部分文章或涉及到的综述

成人患者中达托霉素群体药动学模型的系统评价与研究进展

华旭东，周柳君，俞振伟. 《中国现代应用药学》2026 年 6 月第 43 卷第 11 期

成人患者利奈唑胺群体药代动力学模型的外部验证

房秋，蒋双妙，王晶，罗雪梅，金路，朱怀军.《中国临床药理学与治疗学》2026 年

 其他国家用户发表的部分文章或相关的综述

基于群体药代动力学模型推导儿科剂量的策略

Strategies for pediatric dose derivation from population pharmacokinetic models

Krause A, Cellière G. J Pharmacokinet Pharmacodyn. 2026 Jul 29;53(5):46.

在群体药代动力学建模中，用于处理异常值的重尾残差误差模型比较

Comparing heavy-tailed residual error models for outlier handling in population PK modeling

Yiming Cheng, Yan Li. J Pharmacokinet Pharmacodyn. 2026 Jun 17;53(4):31.

解耦 CAR-T 扩增、转化与衰减时序：基于生理对齐的半机制建模，采用平滑门控与Cauchy似然残差模型

Decoupling CAR-T Expansion, Conversion, and Decay Timing: Physiologically Aligned Semi-Mechanistic Modeling With Smooth Gating and a Cauchy Likelihood Residual Model.

Cheng Y, Li Y. J Clin Pharmacol. 2026 Jul;66(7):e70232.

基于延迟微分方程（DDE）的 CAR-T 细胞动力学建模：应用于 BCMA 靶向（Ide-cel、Orva-cel）和 CD19 靶向（Lisocel）疗法

Delay differential equation (DDE) modeling of CAR-T cellular kinetics: Application to BCMA-targeted (Ide-cel, Orva-cel) and CD19-targeted (Lisocel) therapies.

Cheng Y, Li Y. J Pharm Sci. 2026 May 27;115(8):104346.

PMX-CovEval：包含模拟PK数据库的协变量模型构建方法基准测试框架

PMX-CovEval: A Framework Including a Simulated Pharmacokinetic Database for Covariate Model Building Methods Benchmarking

Mélanie Karlsen, Jérôme Azé 1, Sandra Bringay, Pascal Poncelet, David Fabre, David Marchionni, Elisa A M Calvier. CPT Pharmacometrics Syst Pharmacol. 2026 Jul;15(7):e70278. doi: 10.1002/psp4.70278.

阿奇霉素在未足月胎膜早破中的应用：群体药代动力学与给药剂量优化

Azithromycin in preterm premature rupture of membranes: population pharmacokinetics and dose optimization

Rupsa C Boelig, Kevin Lam, Viren Soni, Ankit Rochani, Gagan Kaushal, Matthew Hoffman, Amanda Roman, Walter K Kraft. Am J Obstet Gynecol. 2026 Mar;234(3):752-769. doi: 10.1016/j.ajog.2025.09.029. Epub 2026 Feb 14.

高强度间歇运动对二甲双胍在健康男性PK的影响：基于群体药代动力学模型的评估

Effect of high-intensity interval exercise on metformin pharmacokinetics in healthy men, assessed through a population pharmacokinetic model

Nikolaidis S, Kosmidis I, Papadopoulos S, Lioupi A, Gandanidou M, Gika H, Dokoumetzidis A, Theodoridis G, Mougios V.  J Pharmacol. 2026 Feb;183(3):438-452.

美罗培南在接受体外膜肺氧合的危重症成年患者中的群体药代动力学：一项 ASAP ECMO 研究

Population pharmacokinetics of meropenem in critically ill adult patients receiving extracorporeal membrane oxygenation-an ASAP ECMO study

Abdul-Aziz MH, Cheng V, Burrows F, Buscher H, Cho YJ, et al. J Antimicrob Chemother. 2026 Mar 4;81(4):dkag090.

对因院内获得性肺炎入住重症监护室（ICU）的患者进行哌拉西林持续输注时，PK-PD目标的达成情况

Pharmacokinetic-pharmacodynamic target attainment with continuous infusion piperacillin in patients admitted to the ICU with hospital-acquired pneumonia

Zurawska M, Valadez A, Harlan E, Williamson R, Scheetz MH, et al. Antimicrob Agents Chemother. 2026 Feb 4;70(2):e0176025.

卡博特韦在 HIV 感染患者中口服和肌内给药期间群体药代动力学模型的外部评价

External Evaluation of Population Pharmacokinetic Models of Cabotegravir, During Its Oral and Intramuscular Administration in HIV-Infected Patients

Renou Q, Néant N, Destere A, Lagoutte-Renosi J, Grégoire M, et al. CPT Pharmacometrics Syst Pharmacol. 2026 Jun;15(6):e70180.

阿替利珠单抗皮下给药的PK见解：标准方案外延长给药间隔的可行性

Pharmacokinetic insights into atezolizumab SC: viability of extended dosing intervals beyond the standard regimen

Gimeno-Ballester V, Herranz-Bayo E, Trigo-Vicente C. Clin Transl Oncol. 2026 Mar 6.

美罗培南群体药代动力学模型在危重肺炎患者中的预测准确性

Predictive accuracy of population meropenem models in critically ill pneumonia patients.

Valadez A, Harlan E, Jeantet C, Scheetz MH, Neely MN, Donnelly HK, Wunderink RG, Rhodes NJ. Antimicrob Agents Chemother. 2026 Jul 10:e0045826.

优化需要间歇性血液透析患者的万古霉素治疗中治疗靶向达标率

Optimising Therapeutic Target Attainment in Vancomycin Therapy for Patients Requiring Intermittent Haemodialysis.

Tsai D, Hernández-Mitre MP, Legg A, Martin J, Sajiv C, Kodgire S, Naughton W, Janson S, Hughes JT, Liu X, Roberts JA. Nephrology (Carlton). 2026 Jul;31(7):e70239.

在急性肾损伤大鼠模型中，海马体和皮层内头孢吡肟浓度升高与癫痫发作呈相关性

Elevated hippocampal and cortical cefepime concentrations correlate with seizures in an acute kidney injury rat model.

Pais GM, Lesnicki E, Marianski S, Valdez K, Gibson Z, Christopher J, Lepard K, Gilchrist A, Mizuno T, Scheetz MH. Antimicrob Agents Chemother. 2026 Apr;70(4):e0100525.

舍曲林在患有焦虑障碍的儿科患者中的剂量-效应关系：一项群体药代动力学分析

Exposure-response relationship of sertraline in pediatric patients with anxiety disorders: a population pharmacokinetic analysis.

Gandara Mireles JA, Cesar Grijalva Avila J, Villanueva Fierro I, et al. Front Pharmacol. 2026 Jun 24;17:1862275

儿童静脉 - 动脉体外膜肺氧合中普通肝素的剂量：2015-2021 年单中心回顾性研究

Unfractionated Heparin Dosing in Pediatric Venoarterial Extracorporeal Membrane Oxygenation: Single-Center Retrospective Study, 2015-2021.

de Cacqueray N, Foissac F, Bouazza N, Gontharet D, et al. Pediatr Crit Care Med. 2026 Mar 1;27(3):244-252.

清髓性造血细胞移植中抗胸腺细胞球蛋白的群体药代动力学与最佳暴露量

Population Pharmacokinetics and Optimal Exposure of Antithymocyte Globulin in Myeloablative Hematopoietic Cell Transplantation.

Ghazal H, Leuchter S, Ngo R, Kinzel M, Dabas R, Dharmani-Khan P, Khan FM, Jamani K, Li N, Kiang TKL, Storek J. Transplant Cell Ther. 2026 May;32(5):577.e1-577.e17.

他克莫司口服混悬液在造血干细胞移植儿童中的群体药代动力学及生物利用度研究

Population pharmacokinetics and bioavailability of tacrolimus oral suspension in children with haematopoietic stem cell transplant.

Brstilo L, Ibarra M, Juliá A, Testard J, Salgueiro R, Mendoza A, Pérez C, Licciardone N, Marquet P, Staciuk R, Buontempo F, Schaiquevich P. Br J Clin Pharmacol. 2026 Jan;92(1):210-219

他克莫司的群体药代动力学及 CYP3A5 驱动的变异性：模型引导的个体化给药在儿童肾移植受试者的应用

Population pharmacokinetics of tacrolimus and CYP3A5-driven variability: implications for model-informed dose individualization in pediatric renal transplant recipients.

Xajil-Ramos LY, Gándara-Mireles JA, Guerra-García M, Rosales RJV, Lou-Meda R. et al.

BMC Pharmacol Toxicol. 2026 Jun 13.

危重症与非危重症住院成年患者中总头孢曲松与游离头孢曲松的群体药代动力学研究

Population pharmacokinetics of total and free ceftriaxone in critically ill and non-critically ill hospitalised adult patients.

Setiawan E, Gonzalez A, Wölky SA, Cotta MO, Liu X, Sosilya H, Abdul-Aziz MH. et al. Int J Antimicrob Agents. 2026 Aug;67(8):107817

多黏菌素 B 在多重耐药鲍曼不动杆菌和铜绿假单胞菌感染危重症患者中的群体药代动力学研究

Population pharmacokinetics of polymyxin B in critically ill patients with multi-drug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa infections.

Zamri PJ, Wölky SA, Hernandez-Mitre MP, Liu X, Hasan MS, Abdul-Aziz MH. et al.

Int J Antimicrob Agents. 2026 Jul;67(7):107816.

基于整合PK/PD模型评估生长分化因子 15 作为蒽环类药物诱导心脏毒性的早期生物标志物

Evaluation of Growth Differentiation Factor 15 as an Early Biomarker of Anthracycline-Induced Cardiotoxicity Using an Integrated PK/PD Model.

Dabour MS, Blaes AH, Jacobson PA, Kirstein MN, Zordoky BN, Cheng S. Clin Transl Sci. 2026 May;19(5):e70595

比较阿达木单抗原研药与生物类似药在炎症性肠病或自身免疫性疾病患者中的PK

Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune disease.

Drweesh H, Alotaibi A, Alqassim HA, Eid MM, Emsaad SA, Alsultan A. et al. Saudi Pharm J. 2026 Mar 17;34(2):14.

舒更葡糖的血浆水平与产后母乳浓度：一项在剖宫产全身麻醉女性中进行的PK研究

Plasma levels and postpartum breastmilk concentrations of sugammadex: a pharmacokinetic study in women undergoing general anaesthesia for caesarean delivery.

Hodge AT, Tognolini AR, Liu X, Won H, Roberts JA, Wallis SC, Woods CA, Eley VA. Int J Obstet Anesth. 2026 May;66:104874

结合动力学在单一靶点介导框架内可解释二肽基肽酶-IV 抑制剂的线性和非线性PK

Binding Kinetics Can Explain Linear and Nonlinear Pharmacokinetics of Dipeptidyl Peptidase-IV Inhibitors Within a Single Target-Mediated Framework.

Elalem A, Ette ME, Mager DE. Pharm Res. 2026 Apr;43(4):1089-1099

免疫抑制剂的药理遗传学和PK：埃及女性狼疮性肾炎患者的临床相关性及疾病活动度控制

Pharmacogenetics and pharmacokinetics of immunosuppressants: clinical correlations and disease activity control in Egyptian female patients with lupus nephritis.

Elmowafy AY, Elwasif S, Shemies R, Abdel-Rahman AM, Malek HA. et al.

Mol Biol Rep. 2026 May 16;53(1):782.

儿童肝移植受者血浆和腹膜液中哌拉西林的群体药代动力学及给药剂量优化：一项 Optimome 研究

Piperacillin Population Pharmacokinetics in Plasma and Peritoneal Fluid and Dosing Optimization in Children Undergoing Liver Transplant: An Optimome Study.

de Cacqueray N, Oualha M, Foissac F, Bournaud LF, Béranger A. et al. Clin Pharmacol Ther. 2026 Aug;120(2):484-491.

利用真实世界数据预测骨肉瘤患儿甲氨蝶呤所致急性肾损伤的模型引导早期预测：一项多中心PK研究

A Model-Informed Early Prediction of Methotrexate-Induced Acute Kidney Injury in Pediatric Patients with Osteosarcoma Using Real-World Data: A Multi-center Pharmacokinetic Study.

Rega P, Vallespin JM, Aldaz A, Pappas A, Guido PC, Schaiquevich P. et al. Clin Pharmacokinet. 2026 Jul;65(7):1101-1112.

哌拉西林/他唑巴坦在脓毒症及脓毒性休克危重患者中PK/PD靶目标达成率的多中心评估及其与临床结局的关联性研究

A multicentre evaluation of pharmacokinetic/pharmacodynamic target attainment of piperacillin and tazobactam and the association with clinical outcomes in critically ill patients with sepsis and septic shock.

Sulaiman H, Wölky SA, Rozali MA, Adiraju SKS, Abdul-Aziz MH. et al. J Antimicrob Chemother. 2026 Jun 3;81(7):dkag199.